Relapsing polychondritis: new therapeutic strategies with biological agents

Paola Sabrina Buonuomo; Claudia Bracaglia; Andrea Campana; Maya El Hachem; Andrea Diociaiuti; Antonella Insalaco; Fabrizio De Benedetti; Beatrice Chiarini Testa; Elisabetta Cortis; Giovanni Carlo De Vincentiis; Alberto G Ugazio

doi:10.1007/s00296-009-0981-9

Relapsing polychondritis: new therapeutic strategies with biological agents

Rheumatol Int. 2010 Mar;30(5):691-3. doi: 10.1007/s00296-009-0981-9. Epub 2009 Aug 15.

Authors

Paola Sabrina Buonuomo¹, Claudia Bracaglia, Andrea Campana, Maya El Hachem, Andrea Diociaiuti, Antonella Insalaco, Fabrizio De Benedetti, Beatrice Chiarini Testa, Elisabetta Cortis, Giovanni Carlo De Vincentiis, Alberto G Ugazio

Affiliation

¹ Department of Pediatrics, Pediatric Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Piazza S. Onofrio, 4, 00135, Rome, Italy. [email protected]

PMID: 19685056
DOI: 10.1007/s00296-009-0981-9

Abstract

Relapsing polychondritis (RP) is a rare disease of unknown etiology characterized by recurrent episodes of inflammation resulting in the destruction of cartilaginous tissues. We describe a young girl with RP unresponsive to conventional therapy.

Publication types

Case Reports

MeSH terms

Adolescent
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Fatal Outcome
Female
Humans
Immunosuppressive Agents / therapeutic use
Infliximab
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Intubation, Intratracheal
Polychondritis, Relapsing / complications
Polychondritis, Relapsing / drug therapy*
Polychondritis, Relapsing / pathology
Pulse Therapy, Drug
Respiration, Artificial
Respiratory Distress Syndrome / etiology
Respiratory Distress Syndrome / therapy
Steroids / administration & dosage
Tracheostomy
Treatment Outcome

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Immunosuppressive Agents
Interleukin 1 Receptor Antagonist Protein
Steroids
Infliximab